Hepatocyte Nuclear Factor 1 Alpha (HNF1A)

Where the papers sit

12 papers from the last 6 months study Hepatocyte Nuclear Factor 1 Alpha (HNF1A) directly · updated from PubMed 5 Oct 2026

• Anti-PD-1 Resistance in Tumors

  Anti-PD-1 resistance is being addressed by rebuilding stem-like CD8+ T-cell pools and intratumoral immune niches. Epigenetic and cytokine therapy, all-trans retinoic acid, and GSK-3 modulation aim to preserve cytolytic function and CD4–CD8 cooperation. Tregs and MHC-I loss remain recurrent routes to immune evasion, especially in metastatic pancreatic cancer. Proteostasis and dendritic-cell support are emerging complementary targets, but durable control still depends on overcoming terminal exhaustion.

  5 papers · 41.7%

• Monogenic Diabetes Gene Editing

  CRISPR/Cas9 repair in patient-derived hiPSCs is moving HNF1A-associated MODY toward experimentally testable, genetically corrected disease models. The work links heterozygous HNF1A mutations to monogenic diabetes phenotypes and uses isogenic comparisons to separate causal effects. Digenic HNF1A and ABCC8 variants broaden the focus from single-gene attribution to modifier and interaction mechanisms. Functional correction and precise genotype interpretation remain the main goals.

  2 papers · 16.7%

• Others — Hepatic Metabolism and Cancer

  HNF-family regulation is being connected to hepatic lipid handling, drug metabolism and epithelial cancer biology. Studies address FXR/PXR-CYP450 responses, atherogenic lipoprotein suppression and HNF4α agonism, while resistance mutations complicate colorectal liver metastases. HNF4α is also pursued as a vulnerability in lung adenocarcinoma, extending metabolic control beyond the liver. The cluster offers no single therapeutic direction, with screening, metabolism and cancer resistance remaining parallel themes.

  5 papers · 41.7%